Amperometric miniaturized enzyme-based nanobiosensor for sensitive detection of sarcosine -potential prostate cancer marker in urine samples

Primárne karty

Amperometric miniaturized enzyme-based nanobiosensor for sensitive detection of sarcosine -potential prostate cancer marker in urine samples

Štefánia Hrončeková1 , Tomáš Bertók , Lenka Lorencová , Ján Tkáč ,
1 Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38 Bratislava, Slovak Republic
hroncekova.stefania@gmail.com

Cancer continues to be a worldwide killer, despite enormous amount of research seen during the past decade. Among men, prostate cancer (PCa) is the most frequently diagnosed cancer disease. Currently, the gold standard in PCa diagnostics is analysis of the prostate specific antigen (PSA) level in blood serum. PSA level is low in healthy men with an increased level found as a result of having either PCa as well as prostate inflammation or benign prostate hyperplasia. Thus, PSA is prostate specific rather than cancer specific. For this purpose, there is a need to find new, more specific biomarkers. This work is focused on the detection of a sarcosine, which can be found in elevated levels in urine during PCa [1]. In this work, 2D nanomaterial MXene Ti3C2Tx was used to immobilise enzyme sarcosine oxidase (SOx) onto the surface of screen-printed carbon electrodes (SPCEs) to fabricate a miniaturized SOx/MXene-chitosan/SPCE nanobiosensor. Quantification of sarcosine was achieved indirectly via amperometric detection of H2O2 produced during the enzymatic reaction. Miniaturized sarcosine nanobiosensor displayed low detection limit of 7.0 nM. Fitting of calibration curve using Hill model and Michaelis-Menten kinetics rendered the following maximum peak current output Imax: (4.10 ± 0.35).10-5 A. The prepared device was further successfully used for sarcosine determination in artificial urine with a recovery index 105.7%.

Poďakovanie: 

The authors would like to acknowledge the financial support received from the Slovak Research and Development Agency APVV 20-0476 and APP 17-0300 and from the Slovak Scientific Grant Agency VEGA 2/0137/18 and 2/0130/20. We would like to acknowledge the support received from the Ministry of Health of the Slovak Republic under the project registration number 2019/68-CHÚSAV-1.

Zdroje: 

[1]        Bertók T. et al.; Novel Prostate Cancer Biomarkers: Aetiology, Clinical Performance and Sensing Applications, Chemosensors, 2021, Vol. 9, art. No. 205.